Published in Pharmacol Ther on January 01, 1985
Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci U S A (1999) 1.55
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer (2008) 1.52
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant (2015) 1.47
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics (2013) 1.30
Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol (2010) 1.21
p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res (2008) 1.14
Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest (1993) 1.08
Aberrant DNA methylation in malignant melanoma. Melanoma Res (2010) 1.04
Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag (2007) 0.94
Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Br J Cancer (1988) 0.92
Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol (2008) 0.92
GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PLoS One (2011) 0.89
DNA methylation: its role in cancer development and therapy. Curr Probl Cancer (2008) 0.88
Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation. Clin Epigenetics (2014) 0.86
The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br J Cancer (1991) 0.86
Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome. Int J Clin Oncol (2013) 0.82
An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. Onco Targets Ther (2010) 0.80
Demethylating Agents in the Treatment of Cancer. Pharmaceuticals (Basel) (2010) 0.77
Transbuccal delivery of 5-aza-2 -deoxycytidine: effects of drug concentration, buffer solution, and bile salts on permeation. AAPS PharmSciTech (2007) 0.76
Promising approaches in acute leukemia. Invest New Drugs (2000) 0.75
Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case-control study. N Engl J Med (1991) 4.17
Fetal loss associated with caffeine intake before and during pregnancy. JAMA (1994) 3.72
Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost (2006) 2.57
The effect of cooling on coagulation and haemostasis: should "Ice" be part of treatment of acute haemarthrosis in haemophilia? Haemophilia (2012) 2.47
Partial purification and properties of two forms of deoxyribonucleic acid polymerase from calf thymus. J Biol Chem (1973) 2.31
Effect of cytosine arabinoside 5'-triphosphate on mammalian DNA polymerase. Biochem Biophys Res Commun (1969) 2.16
Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res (1976) 1.70
Pregnancy loss and work schedule during pregnancy. Epidemiology (1993) 1.54
Successful treatment of Kasabach-Merritt syndrome with prednisone and epsilon-aminocaproic acid. Pediatr Hematol Oncol (1992) 1.54
Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia (2005) 1.52
A trial of desmopressin to reduce blood loss in patients undergoing spinal fusion for idiopathic scoliosis. Anesth Analg (1992) 1.49
Epstein-Barr virus polymorphic B-cell lymphoma associated with leukemia and with congenital immunodeficiencies. J Clin Oncol (1990) 1.48
A model for the chemotherapy of acute leukemia with 1-beta-D-arabinofuranosylcytosine. Cancer Res (1974) 1.48
Incorporation of 5-Aza-2'-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol (1983) 1.37
International workshop on immune tolerance induction: consensus recommendations. Haemophilia (2007) 1.37
Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol (1997) 1.34
Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol (1983) 1.24
The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br J Haematol (2000) 1.20
Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res (1983) 1.19
Minor histocompatibility antigens. Blood (1990) 1.18
Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol (1993) 1.15
Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. Leuk Res (1981) 1.15
Study of Langerhans cells after allogeneic bone marrow transplantation. Blood (1984) 1.11
Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia (2011) 1.11
Persistence of host Langerhans cells following allogeneic bone marrow transplantation: possible relationship with acute graft-versus-host disease. Br J Haematol (1985) 1.09
Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine. Pharmacol Ther (1985) 1.08
Lymphoid interstitial pneumonia after allogeneic bone marrow transplantation. A possible manifestation of chronic graft-versus-host disease. Cancer (1985) 1.07
Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol (1992) 1.07
Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J Biol Chem (1968) 1.06
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia (2006) 1.04
Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res (1984) 1.04
In vitro cytotoxic and biochemical effects of 5-aza-2'-deoxycytidine. Cancer Res (1977) 1.04
Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol (2001) 1.03
Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2'-deoxycytidine in rabbits and dogs. Cancer Res (1983) 1.03
Kinetic and template studies with 1- -D-arabinofuranosylcytosine 5'-triphosphate and mammalian deoxyribonucleic acid polymerase. Mol Pharmacol (1972) 1.03
Gaucher disease: variability in phenotype among siblings. J Inherit Metab Dis (2004) 1.03
Factor VIIa replacement therapy in factor VII deficiency. J Thromb Haemost (2004) 1.02
Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood (2001) 1.02
DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine. Anticancer Drugs (1999) 1.01
Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside. Biochim Biophys Acta (1968) 1.01
Thrombin generation and bleeding in haemophilia A. Haemophilia (2009) 1.01
Mycobacterium tuberculosis infection in allogeneic bone marrow transplantation patients. Bone Marrow Transplant (1999) 1.00
Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs (1998) 1.00
Mammalian deoxynucleoside kinases. II. Deoxyadenosine kinase: purification and properties. J Biol Chem (1971) 0.99
Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost (1995) 0.98
Kinetics of phosphorylation of 5-aza-2'-deoxyycytidine by deoxycytidine kinase. Biochem Pharmacol (1979) 0.97
Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine. Leuk Res (1985) 0.97
Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant (2002) 0.97
A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia (2008) 0.96
Cell cycle effects and cellular pharmacology of 5-aza-2'-deoxycytidine. Cancer Chemother Pharmacol (1984) 0.95
Empirical and theoretical phenotypic discrimination. J Thromb Haemost (2009) 0.95
High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine. J Pharm Sci (1981) 0.94
Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol (1998) 0.93
Vibrissa-related behavior in mice: transient effect of ablation of the barrel cortex. Behav Brain Res (1991) 0.90
Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res (1994) 0.90
An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia (2012) 0.90
Relative sensitivity of different tests in the detection of low titer lupus anticoagulants. Thromb Haemost (1988) 0.89
Audience effects on alarm calling in chickens (Gallus gallus). J Comp Psychol (1988) 0.89
Mediastinal bleeding after cardiopulmonary bypass in pediatric patients. Ann Thorac Surg (1996) 0.89
Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone. Bone Marrow Transplant (2007) 0.88
Thymic and extrathymic differentiation and expansion of T lymphocytes following bone marrow transplantation in irradiated recipients. Exp Hematol (1997) 0.88
Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: better in the evening. Lancet (1985) 0.88
Beneficial effects of fish-oil supplements on lipids, lipoproteins, and lipoprotein lipase in patients with glycogen storage disease type I. Am J Clin Nutr (1993) 0.86
A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia. A peculiar pathologic aspect of busulfan lung? Cancer (1984) 0.86
Activation of the retinoic acid receptor beta gene by 5-aza-2'-deoxycytidine in human DLD-1 colon carcinoma cells. Anticancer Drugs (1997) 0.86
Tissue factor enhances protease-activated receptor-2-mediated factor VIIa cell proliferative properties. J Thromb Haemost (2005) 0.86
Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci (1998) 0.86
Possible C1q bypass loop activation in the haemolytic uraemic syndrome. Clin Exp Immunol (1979) 0.85
Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus. Cancer Res (1974) 0.85
Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest (1984) 0.84
Recurrent localised pneumonia due to bronchial infiltration in a patient with chronic lymphocytic leukaemia. Thorax (1990) 0.84
Sample preparation for the determination of 5-aza-2'-deoxycytidine in plasma by high-performance liquid chromatography. J Chromatogr (1985) 0.83
Studies on the phosphorylation of cytosine arabinoside in mammalian cells. Mol Pharmacol (1971) 0.83
Effects of 5-aza-2'-deoxycytidine on survival and cell cycle progression of L1210 leukemia cells. Leuk Res (1986) 0.83
Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma. Genes Chromosomes Cancer (1999) 0.83
Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia. Cancer Treat Rep (1984) 0.83
Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia (2008) 0.83
Stereological analysis of subchondral angiogenesis induced by chitosan and coagulation factors in microdrilled articular cartilage defects. Osteoarthritis Cartilage (2013) 0.82
Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost (2014) 0.82
Effect of DNA polymerase on nuclei from different phases of cell cycle. Eur J Biochem (1974) 0.82
Factor V Quebec revisited. Blood (1996) 0.81
Primary infection by Epstein-Barr virus presenting as aplastic anemia. N Engl J Med (1983) 0.81
Mammalian deoxynucleoside kinases. 3. Deoxyadenosine kinase: inhibition by nucleotides and kinetic studies. J Biol Chem (1971) 0.81
Incorporation of hypoxanthine into adenine and guanine nucleotides by human platelets. Biochim Biophys Acta (1975) 0.81
Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene. Cancer Gene Ther (2001) 0.81
Serum immunoglobulin levels following allogeneic bone marrow transplantation. Blut (1985) 0.81
Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk Res (1995) 0.81
Hemolytic uremic syndrome; treatment with plasma, vitamin E and cod liver oil. Int J Pediatr Nephrol (1983) 0.81
Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy. J Clin Invest (1995) 0.81
Cofactor of the "lupus anticoagulant". Thromb Diath Haemorrh (1974) 0.81